Consolidation Treatment with VRD Followed By Maintenance with Lenalidomide in Multiple Myeloma Improves Overall Survival: Long-Term Follow-up of the EMN02/HOVON95 Randomized Phase 3 Trial

AIM. To evaluate the long-term overall survival (OS) associated with bortezomib-lenalidomide-dexamethasone (VRD) consolidation treatment in transplant-eligible patients with newly diagnosed multiple myeloma (NDTE-MM). METHODS. The EMN02/HOVON95 trial compared consolidation treatment with 2 cycles of...

Full description

Saved in:
Bibliographic Details
Published in:Blood 2024-11, Vol.144, p.674-674
Main Authors: Sonneveld, Pieter, Dimopoulos, Meletios A., Beksac, Meral, van der Holt, Bronno, Gay, Francesca, Ludwig, Heinz, Zweegman, Sonja, Maisnar, Vladimir, Petrucci, Maria Teresa, Corradini, Paolo, Patriarca, Francesca, Belotti, Angelo, Quaresima, Micol, Grasso, Mariella, Offidani, Massimo, Paris, Laura, Liberati, Anna Marina, Hansson, Markus, Visser-Wisselaar, Heleen, Fumero, Giulia, Zambello, Renato, Ypma, Paula F, Pascarella, Anna, Frost Andersen, Niels, Croockewit, Alexandra, Boccadoro, Mario, Cavo, Michele
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:AIM. To evaluate the long-term overall survival (OS) associated with bortezomib-lenalidomide-dexamethasone (VRD) consolidation treatment in transplant-eligible patients with newly diagnosed multiple myeloma (NDTE-MM). METHODS. The EMN02/HOVON95 trial compared consolidation treatment with 2 cycles of VRD or no consolidation followed by continuous lenalidomide maintenance until progression or intolerance. The primary study endpoint was progression-free survival (PFS). Here we report the secondary endpoint OS. This trial is registered with the EU Clinical Trials Register (EudraCT 2009-017903-28) and ClinicalTrials.gov (NCT01208766). RESULTS. In the EMN02/HOVON95 trial, 1503 NDTE-MM patients were enrolled, 1500 of whom were eligible. Patients received induction treatment with bortezomib-cyclophosphamide-dexamethasone (VCD) followed by the first randomisation (R1) for intensification with single or double high-dose melphalan plus autologous stem-cell transplantation (HDM1/2-ASCT) or bortezomib-melphalan-prednisone (VMP; Cavo et al. Lancet Haematology 2020; 7(6): e456-e468). Subsequently, eligible patients were randomized (R2) to receive VRD consolidation (n=451) or no consolidation (n=427). As reported before, the rates of complete response or better (≥CR) after consolidation vs no consolidation before the start of lenalidomide maintenance were 34% vs 18%, respectively (p
ISSN:0006-4971
DOI:10.1182/blood-2024-197908